All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

FDA approves Bayer's Lynkuet elinzanetant targeting NK1/NK3 receptors for moderate to severe vasomotor symptoms of menopause
Small molecule, women's health, neurokinin receptor antagonist, menopause, vasomotor symptoms - Read more

THE GOOD
Business Development & Partnerships

Biogen, Vanqua Bio license anti-inflammatory C5aR1 antagonist, $70M upfront, $990M milestones
Licensing deal, immunology, anti-inflammatory, small molecule, milestone payments - Read more

Labcorp, Roche partner to offer FDA-cleared Alzheimer's blood test for cognitive decline assessment
Commercialization agreement, neurological, diagnostics, blood biomarkers - Read more

Eli Lilly, Cipla partner to distribute and promote Mounjaro diabetes drug in India
Distribution agreement, diabetes, manufacturing, commercialization - Read more

Genenta, Anemocyte expand partnership for off-the-shelf lentiviral vector plasmid DNA production platform
Strategic partnership, gene therapy, manufacturing, plasmid DNA technology - Read more

Takeda, TetraScience launch SAIL program for AI-powered drug discovery and manufacturing acceleration
Research collaboration, AI/ML, drug discovery, R&D, manufacturing - Read more

Kura Oncology, Kyowa Kirin collaboration reaches $30 million milestone for ziftomenib AML Phase 3 trials
Milestone payments, oncology, small molecule, R&D - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

✅ More Good News ✅

THE GOOD
Clinical Trials

Halda's HLD-0915 RIPTAC therapy shows early Ph1/2 activity in metastatic castration-resistant prostate cancer
Small molecule, cancer, RIPTAC platform, metastatic castration-resistant prostate cancer, androgen receptor - Read more

ITM's Lu-edotreotide shows superior response rates vs everolimus in Ph3 gastroenteropancreatic neuroendocrine tumors trial
Radiopharmaceutical, cancer, lutetium-177, neuroendocrine tumors, somatostatin receptor - Read more

Incyte reports positive Ph3b results for Opzelura (ruxolitinib) cream targeting JAK pathway in moderate atopic dermatitis
Small molecule, autoimmune, JAK inhibitor, atopic dermatitis, topical therapy - Read more

Remix Therapeutics reports 43% response rate for RMX-1001 mRNA degrader targeting MYB in adenoid cystic carcinoma Ph1 trial
Small molecule, cancer, mRNA degrader, adenoid cystic carcinoma, MYB target - Read more

Zai Lab reports Ph1 data for zocilurtatug pelitecan DLL3-targeting ADC in extensive-stage small cell lung cancer
Antibody-drug conjugate, cancer, small cell lung cancer, DLL3 target, platinum-resistant - Read more [Paywall]

Merus reports positive Ph2 interim data for petosemtamab EGFR/LGR5 bispecific in metastatic colorectal cancer
Antibody, cancer, bispecific antibody, metastatic colorectal cancer, EGFR target, LGR5 target - Read more

THE GOOD
Earnings & Finances

Sanofi's Dupixent hits record €4.2B ($4.88B) quarterly sales, offsetting 8% decline in vaccine revenue
Monoclonal antibody, autoimmune, financial, revenue impact - Read more

THE GOOD
Fundraises

MediMabBio raises $17M Series B, advancing fusion-antibody immunotherapies and global partnerships
Autoimmune, antibody, fusion protein, immunotherapy, platform technology - Read more

Starna Therapeutics raises $47M Series B, targeted delivery platform and CAR-T pipeline
CAR-T, targeted delivery platform, oncology, RNA therapeutics, clinical-stage - Read more

X4 Pharmaceuticals raises $135M public offering for rare disease drug development
Small molecule, rare disease, clinical-stage, CXCR4 antagonist - Read more

Coya Therapeutics raises $20M public offering, Treg-focused neurodegenerative disorder treatments
Neurological, biologics, clinical-stage, regulatory T cell - Read more

THE GOOD
Mergers & Acquisitions

Eli Lilly acquires Adverum Biotechnologies for up to $262M, expanding gene therapy portfolio
Gene therapy, ophthalmology, strategic, major transaction - Read more

Roche's Chugai acquires Renalys Pharma for $200M, gaining sparsentan IgAN rights across Asia
Small molecule, rare disease, strategic, major transaction - Read more

Novartis acquires Avidity Biosciences for $12B to strengthen neuromuscular disease pipeline with RNA therapeutics
RNA therapeutics, neuromuscular, strategic, major transaction - Read more

THE BAD
Clinical Trials

Sanofi terminates SP0125 respiratory syncytial virus vaccine for toddlers after Ph3 futility analysis
Vaccine, infectious disease, live attenuated vaccine, respiratory syncytial virus, pediatric population - Read more

Guard Therapeutics' RMC-035 kidney-protective treatment fails Ph2b POINTER study primary and secondary endpoints
Small molecule, kidney disease, RMC-035, phase 2b trial, nephroprotective therapy - Read more

THE BAD
Earnings & Finances

Sanofi reports 7.8% quarterly vaccine sales drop amid soft US flu immunization rates
Vaccine, infectious disease, financial, competitive, revenue impact - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here